Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1121444 | 0.88 | ALDH1A3 (0.63) | ALDH1A3ERN1ALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL12037831 | 0.88 | ALDH1A3 (0.63) | ALDH1A3ERN1ALDH1A1KMT2AHPGD | |
| SCHEMBL10768894 | 0.81 | CA12 (0.45) | ALDH1A3ALDH1A1BACE1CYP1A1PTGS2 | |
| SCHEMBL5233624 | 0.81 | ALDH1A1 (0.42) | ALDH1A3ALDH1A1BACE1KMT2ACA12 | |
| SCHEMBL22779349 | 0.81 | ALDH1A3 (0.55) | ALDH1A3ERN1ALDH1A1TTRCYP1A1 | |
| SCHEMBL21945477 | 0.81 | DRD1 (0.50) | ALDH1A3ALDH1A1BACE1TTRCYP1A1 | |
| SCHEMBL14018645 | 0.81 | ALDH1A3 (0.55) | ALDH1A3ERN1ALDH1A1KMT2AHPGD | |
| SCHEMBL16034438 | 0.80 | ALDH1A3 (0.50) | ALDH1A3ERN1ALDH1A1KMT2ATP53 | |
| SCHEMBL12038129 | 0.79 | ALDH1A3 (0.53) | ALDH1A3ERN1ALDH1A1KMT2AHPGD | |
| SCHEMBL20881111 | 0.79 | ALDH1A3 (0.49) | ALDH1A3ERN1ALDH1A1KMT2APARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459883-B2 | Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof | Kynan Duke IP, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-20230159421-A1 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | Kynan Duke IP, LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159421-A1 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | Kynan Duke IP, LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159421-A1 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | Kynan Duke IP, LLC (US) | 2023-05-25 | — | — | US | disclosed |
| CN-115485259-A | Substituted hydroxystilbene compounds and derivatives, synthesis and use thereof | 凯楠公爵IP有限责任公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021127743-A1 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | Kynan Duke IP, LLC (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021127743-A1 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | Kynan Duke IP, LLC (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-1846402-B1 | 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| EP-1846402-B1 | 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| CN-101506165-B | Phenyl, pyridine and quinoline derivatives | HOFFMANN LA ROCHE | 2012-07-04 | — | — | CN | disclosed |
| EP-1149069-B1 | PHENYLGLYCINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2004-02-19 | — | — | US | disclosed |
| US-6683215-B2 | TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION AND ARTERIOSCLEROSIS, WHICH ARE ASSOCIATED WITH COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA AND TISSUE FACTOR; ANTIINFLAMMATORY AGENTS | HOFFMAN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2003-05-01 | — | — | US | disclosed |
| US-6476264-B2 | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. | 2002-11-05 | — | — | US | disclosed |
| CN-1334798-A | Phenylglycine derivatives | HOFFMANN LA ROCHE (CH) | 2002-02-06 | — | — | CN | disclosed |
| EP-1149069-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6242644-B1 | FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2001-05-24 | — | — | US | disclosed |
| WO-2000035858-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | ALDH1A3 4445/4885ERN1 1281/4885ALDH1A1 2850/4885 |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | ALDH1A3 4445/4885ERN1 1281/4885ALDH1A1 2850/4885 |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | ALDH1A3 4445/4885ERN1 1281/4885ALDH1A1 2850/4885 |
| US-12459883-B2 | Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof | CYP8B1, HSD11B1, HSD11B2 | ALDH1A3 430/4885ERN1 2632/4885ALDH1A1 288/4885 |
| US-20230159421-A1 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | CYP8B1, HSD11B1, HSD11B2 | ALDH1A3 430/4885ERN1 2632/4885ALDH1A1 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.